Search research articles
Contact Us
Filters
Showing results (231-240 of 298) with videos related to
Page
of 30
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
November 17, 2025
[18F]FDG-PET/CT-based evaluation of tumor response kinetics during induction chemotherapy and concurrent radiochemotherapy in stage II - III small-cell lung cancer
Christian Hoffmann, Hubertus Hautzel, Marcel Wiesweg, et al.
Cancers
|
February 24, 2024
LIONS PREY: A New Logistic Scoring System for the Prediction of Malignant Pulmonary Nodules
Fabian Doerr, Annika Giese, Katja Höpker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2022
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
Martin Schuler, Lisa Zimmer, Kevin B Kim, et al.
The Lancet. Oncology
|
August 14, 2019
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
Martin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, et al.
International Journal of Cancer
|
September 25, 2024
Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome
Marcel Wiesweg, Claudia Küter, Johannes Schnorbach, et al.
Journal of Cancer Research and Clinical Oncology
|
February 21, 2019
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
Martin Schuler, Eng-Huat Tan, Kenneth O'Byrne, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 3, 2024
Fibroblast Activation Protein-Directed Imaging Outperforms <sup>18</sup>F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial
Lukas Kessler, Felix Schwaning, Martin Metzenmacher, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 31, 2016
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer
Marcel Wiesweg, Wilfried E E Eberhardt, Henning Reis, et al.
Cancer Chemotherapy and Pharmacology
|
June 9, 2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E Krop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)
Wilfried Ernst Erich Eberhardt, Christoph Pöttgen, Thomas Christoph Gauler, et al.
Page
of 30
Search research articles
Search
Showing results (231-240 of 298) with videos related to
Sort By:
Page
of 30
European Journal of Nuclear Medicine and Molecular Imaging
|
November 17, 2025
[18F]FDG-PET/CT-based evaluation of tumor response kinetics during induction chemotherapy and concurrent radiochemotherapy in stage II - III small-cell lung cancer
Christian Hoffmann, Hubertus Hautzel, Marcel Wiesweg, et al.
Cancers
|
February 24, 2024
LIONS PREY: A New Logistic Scoring System for the Prediction of Malignant Pulmonary Nodules
Fabian Doerr, Annika Giese, Katja Höpker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2022
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
Martin Schuler, Lisa Zimmer, Kevin B Kim, et al.
The Lancet. Oncology
|
August 14, 2019
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
Martin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, et al.
International Journal of Cancer
|
September 25, 2024
Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome
Marcel Wiesweg, Claudia Küter, Johannes Schnorbach, et al.
Journal of Cancer Research and Clinical Oncology
|
February 21, 2019
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
Martin Schuler, Eng-Huat Tan, Kenneth O'Byrne, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 3, 2024
Fibroblast Activation Protein-Directed Imaging Outperforms <sup>18</sup>F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial
Lukas Kessler, Felix Schwaning, Martin Metzenmacher, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 31, 2016
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer
Marcel Wiesweg, Wilfried E E Eberhardt, Henning Reis, et al.
Cancer Chemotherapy and Pharmacology
|
June 9, 2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E Krop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)
Wilfried Ernst Erich Eberhardt, Christoph Pöttgen, Thomas Christoph Gauler, et al.
Page
of 30